The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis

Published:2023-09 Issue:9 Volume:6 Page:
ISSN:2398-8835
Container-title:Health Science Reports
language:en
Short-container-title:Health Science Reports

Author:

Kow Chia Siang¹^ORCID,Ramachandram Dinesh Sangarran²,Hasan Syed Shahzad³⁴

Affiliation:

1. Department of Pharmacy Practice School of Pharmacy, International Medical University Kuala Lumpur Malaysia

2. School of Pharmacy Monash University Malaysia Bandar Sunway Selangor Malaysia

3. Department of Pharmacy School of Applied Sciences, University of Huddersfield Huddersfield UK

4. School of Biomedical Sciences & Pharmacy University of Newcastle Callaghan Australia

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hsr2.1549

Reference25 articles.

1. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?

2. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

3. Meta‐analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy;Liu W;Exp Ther Med,2019

4. Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

5. A randomized study to compare the effects of once‐weekly dulaglutide injection and once‐daily glimepiride on glucose fluctuation of type 2 diabetes mellitus patients: a 26‐week follow‐up;Li H;J Diabetes Res,2019